Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
Novartis reported cancer cases in nine people who received its gene therapy Zolgensma, including two cases with evidence that the viral delivery tool integrated into patient DNA. The findings could prompt further questions about the safety of gene therapies and their delivery mechanisms.
Novartis Zolgensma gene therapy cancer cases viral vector